Yang Luo

2.5k total citations
135 papers, 1.5k citations indexed

About

Yang Luo is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Yang Luo has authored 135 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 84 papers in Oncology, 52 papers in Cancer Research and 49 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Yang Luo's work include Cancer Treatment and Pharmacology (39 papers), Breast Cancer Treatment Studies (36 papers) and HER2/EGFR in Cancer Research (35 papers). Yang Luo is often cited by papers focused on Cancer Treatment and Pharmacology (39 papers), Breast Cancer Treatment Studies (36 papers) and HER2/EGFR in Cancer Research (35 papers). Yang Luo collaborates with scholars based in China, United States and Japan. Yang Luo's co-authors include Fei Ma, Pin Zhang, Ying Fan, Binghe Xu, Ruigang Cai, Qiao Li, Shanshan Chen, Jiayu Wang, Qing Li and Jiayu Wang and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Yang Luo

122 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yang Luo China	21	989	529	476	371	236	135	1.5k
Zhimin Shao China	22	1.1k 1.2×	557 1.1×	557 1.2×	516 1.4×	290 1.2×	90	1.8k
Akihiko Shimomura Japan	22	1.1k 1.1×	537 1.0×	536 1.1×	751 2.0×	331 1.4×	132	2.0k
Konstantinos Venetis Italy	22	746 0.8×	350 0.7×	295 0.6×	316 0.9×	196 0.8×	70	1.2k
Arlene Berman United States	22	1.3k 1.3×	534 1.0×	474 1.0×	614 1.7×	284 1.2×	47	2.4k
Cristiano Ferrario Canada	18	1.3k 1.3×	653 1.2×	515 1.1×	476 1.3×	208 0.9×	81	1.9k
Jin‐Hee Ahn South Korea	25	938 0.9×	484 0.9×	821 1.7×	549 1.5×	295 1.3×	115	1.9k
Xiaoyu Tu China	13	688 0.7×	305 0.6×	567 1.2×	520 1.4×	151 0.6×	39	1.5k
Akihiko Osaki Japan	23	747 0.8×	528 1.0×	283 0.6×	529 1.4×	325 1.4×	116	1.7k
Estela Pineda Spain	16	669 0.7×	692 1.3×	354 0.7×	624 1.7×	155 0.7×	65	1.6k
Min Hye Jang South Korea	20	1.0k 1.0×	473 0.9×	279 0.6×	610 1.6×	219 0.9×	42	1.7k

Countries citing papers authored by Yang Luo

Since Specialization

Citations

This map shows the geographic impact of Yang Luo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yang Luo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yang Luo more than expected).

Fields of papers citing papers by Yang Luo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yang Luo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yang Luo. The network helps show where Yang Luo may publish in the future.

Co-authorship network of co-authors of Yang Luo

This figure shows the co-authorship network connecting the top 25 collaborators of Yang Luo. A scholar is included among the top collaborators of Yang Luo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yang Luo. Yang Luo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lan, Bo, Jiayu Wang, Qiao Li, et al.. (2025). The ideal strategies of antibody‒drug conjugate sequential treatment in HER2-expressing metastatic breast cancer: A multi-center real-world study. The Breast. 81. 104470–104470. 3 indexed citations

Luo, Yang, Zihan Wu, Xuedong Bai, et al.. (2025). Fluorescence imaging of vascular endothelial growth factor receptor 2 expression in colorectal cancer. Sensors and Actuators B Chemical. 442. 137934–137934.

Satoh, Yusuke, Ryodai Yamamura, Takako Ooshio, et al.. (2025). Inhibition of NAD-GPx4 axis and MEK triggers ferroptosis to suppress pancreatic ductal adenocarcinoma. Molecular Therapy. 33(9). 4618–4635.

Xu, Binghe, Qingyuan Zhang, Yang Luo, et al.. (2025). Lerociclib plus fulvestrant in patients with HR+/HER2− locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trial. Nature Communications. 16(1). 716–716. 2 indexed citations

Wu, Xu, et al.. (2025). The Prognostic Role of Interferon Gamma-inducible Protein 30 in ClearCell Renal Cell Carcinoma with Immune Infiltrates. Recent Patents on Anti-Cancer Drug Discovery. 21.

Chen, Xi, Lei Ji, Min Xiao, et al.. (2024). Evolution and prognostic significance of HER-2 changes from primary to residual disease in patients with HER-2–negative breast cancer receiving neoadjuvant chemotherapy.. Journal of Clinical Oncology. 42(16_suppl). 583–583.

Song, Ge, Min Xiao, Xi Chen, et al.. (2024). Subdivision of M1 category and prognostic stage for de novo metastatic breast cancer to enhance prognostic prediction and guide the selection of locoregional therapy. Thoracic Cancer. 15(30). 2193–2205. 2 indexed citations

Liu, Jiaxuan, Xin Wang, Yipeng Wang, et al.. (2023). Efficacy and safety of apatinib combined with dose‐dense paclitaxel and carboplatin in neoadjuvant therapy for locally advanced triple‐negative breast cancer: A prospective cohort study with propensity‐matched analysis. International Journal of Cancer. 154(1). 133–144. 4 indexed citations

Lu, Yuan, Xiang Wang, Fan Yin, et al.. (2023). [Dose-dense paclitaxel plus carboplatin in combination with trastuzumab neoadjuvant versus standard adjuvant therapy in human epidermal growth factor receptor-2 positive and hormone receptor negative breast cancer: a prospective cohort study].. PubMed. 45(8). 709–716. 2 indexed citations

10.

Luo, Yang, et al.. (2023). DOA estimation based on a deep neural network under impulsive noise. Signal Image and Video Processing. 18(1). 785–792. 2 indexed citations

11.

Wang, Jiayu, Fei Ma, Yang Luo, et al.. (2020). Platinum‐based chemotherapy in advanced triple‐negative breast cancer: A multicenter real‐world study in China. International Journal of Cancer. 147(12). 3490–3499. 9 indexed citations

12.

Li, Qiao, Xiuwen Guan, Shanshan Chen, et al.. (2019). Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial. Clinical Cancer Research. 25(17). 5212–5220. 61 indexed citations

13.

Luo, Yang, Wěi Li, Zefei Jiang, et al.. (2019). Pharmacokinetics of pertuzumab administered concurrently with trastuzumab in Chinese patients with HER2-positive early breast cancer. Anti-Cancer Drugs. 30(8). 866–872. 3 indexed citations

14.

Lan, Bo, Fei Ma, Xiaoyu Zhai, et al.. (2018). The relationship between the CYP2D6 polymorphisms and tamoxifen efficacy in adjuvant endocrine therapy of breast cancer patients in Chinese Han population. International Journal of Cancer. 143(1). 184–189. 27 indexed citations

15.

Lan, Bo, Fei Ma, Shanshan Chen, et al.. (2018). The Effect of Polymorphism in UGT1A4 on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Patients With Breast Cancer in China. Clinical Breast Cancer. 19(2). e370–e375. 5 indexed citations

16.

Lan, Bo, Fei Ma, Shanshan Chen, et al.. (2018). Toremifene, rather than tamoxifen, might be a better option for the adjuvant endocrine therapy in CYP2D6*10T/T genotype breast cancer patients in China. International Journal of Cancer. 143(10). 2499–2504. 16 indexed citations

17.

Zhang, Tongtong, Qing Li, Shanshan Chen, et al.. (2016). Phase I study of QLNC120, a novel EGFR and HER2 kinase inhibitor, in pre-treated patients with HER2-overexpressing advanced breast cancer. Oncotarget. 8(22). 36750–36760. 5 indexed citations

18.

Du, Feng, Peng Yuan, Jiayu Wang, et al.. (2015). Effect of Hormone Therapy on Long-term Outcomes of Patients with Human Epidermal Growth Factor Receptor 2-and Hormone Receptor-Positive Metastatic Breast Cancer: Real World Experience in China. Asian Pacific Journal of Cancer Prevention. 16(3). 903–907. 2 indexed citations

19.

Xu, Yingying, Yong Zhang, Zhenning Wang, et al.. (2009). Role of heparanase-1 in gastric carcinoma invasion.. PubMed. 10(1). 151–4. 10 indexed citations

20.

Liang, Ziwen, et al.. (1995). [Detection of the expression of P21, P53, P185 proteins and the mutation of ras, p53 genes in colorectal adenoma and carcinoma].. PubMed. 24(6). 352–5. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact